Radiolabeled amino acids: basic aspects and clinical applications in oncology
- PMID: 11337520
Radiolabeled amino acids: basic aspects and clinical applications in oncology
Abstract
As the applications of metabolic imaging are expanding, radiolabeled amino acids may gain increased clinical interest. This review first describes the basic aspects of amino acid metabolism, then continues with basic aspects of radiolabeled amino acids, and finally describes clinical applications, with an emphasis on diagnostic value. A special focus is on (11)C-methionine, (11)C-tyrosine, and (123)I-iodomethyltyrosine, because these have been most used clinically, although their common affinity for the L-transport systems may limit generalization to other classes of amino acids. The theoretic and preclinical background of amino acid imaging is sound and supports clinical applications. The fact that amino acid imaging is less influenced by inflammation may be advantageous in comparison with (18)F-FDG PET imaging, although tumor specificity is not absolute. In brain tumor imaging, the use of radiolabeled amino acids is established, the diagnostic accuracy of amino acid imaging seems adequate, and the diagnostic value seems advantageous. The general feasibility of amino acid imaging in other tumor types has sufficiently been shown, but more research is required in larger patient series and in well-defined clinical settings.
Similar articles
-
PET with radiolabeled aminoacid.Q J Nucl Med Mol Imaging. 2012 Apr;56(2):151-62. Q J Nucl Med Mol Imaging. 2012. PMID: 22617237 Review.
-
[Diagnostic value of positron emission tomography (PET) in clinical oncology].Dtsch Med Wochenschr. 2000 May 5;125(18):565-7. doi: 10.1055/s-2007-1024342. Dtsch Med Wochenschr. 2000. PMID: 10835983 Review. German. No abstract available.
-
Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.J Nucl Med. 2003 Apr;44(4):533-9. J Nucl Med. 2003. PMID: 12679396 Clinical Trial.
-
Clinical applications of PET in oncology.Radiology. 2004 May;231(2):305-32. doi: 10.1148/radiol.2312021185. Epub 2004 Mar 24. Radiology. 2004. PMID: 15044750 Review.
-
[The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology].Vopr Onkol. 2003;49(5):563-73. Vopr Onkol. 2003. PMID: 14682126 Russian.
Cited by
-
Differentiation of malignant tumours from granulomas by using dynamic [(18)F]-fluoro-L-α-methyltyrosine positron emission tomography.EJNMMI Res. 2015 Apr 30;5:29. doi: 10.1186/s13550-015-0109-z. eCollection 2015. EJNMMI Res. 2015. PMID: 25977883 Free PMC article.
-
Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.Sci Rep. 2019 Nov 28;9(1):17794. doi: 10.1038/s41598-019-54398-2. Sci Rep. 2019. PMID: 31780768 Free PMC article.
-
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):39-51. doi: 10.1007/s00259-004-1564-3. Epub 2004 Aug 10. Eur J Nucl Med Mol Imaging. 2005. PMID: 15309329
-
Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):792-800. doi: 10.1007/s00259-005-0053-7. Epub 2006 Mar 21. Eur J Nucl Med Mol Imaging. 2006. PMID: 16550381 Free PMC article. Clinical Trial.
-
High uptake on 11C-methionine positron emission tomographic scan of basal ganglia germinoma with cerebral hemiatrophy.AJNR Am J Neuroradiol. 2003 Oct;24(9):1909-11. AJNR Am J Neuroradiol. 2003. PMID: 14561627 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials